28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
Patients with Alzheimer disease (AD) commonly exhibit psychosis and behavioral disturbances that impair patient functioning, create caregiver distress, and lead to institutionalization. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Published studies suggest that greater adherence to Mediterranean diet is associated with slower cognitive decline and lower risk of developing Alzheimer disease. 4 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Atorvastatin treatment may be of some clinical benefit and could be established as an effective therapy for Alzheimer disease if the current findings are substantiated by a much larger multicenter trial. 3 key findings →
Participants: 98 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The findings support the clinical efficacy of CR in early-stage AD. 1 key finding →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In this trial, memantine did not show an advantage over placebo based on protocol-specified primary or secondary analyses in patients with mild to moderate AD on stable ChEI regimens. 2 key findings →
Participants: 433 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Statistically significant effects of AZD0530 treatment were not found on relative CMRgl reduction in an Alzheimer disease-associated region of interest or on secondary clinical or biomarker measures. 3 key findings →
Participants: 159 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Cognitive decline over 36 months of continuous galantamine treatment was substantially less than the predicted cognitive decline of untreated patients with mild to moderate dementia. 5 key findings →
Design: open-label trial Participants: 119 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Preparations based on special extracts of the Ginkgo biloba tree are popular in various European countries. 3 key findings →
Participants: 79 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Among the 158 participants who accurately recalled their Alzheimer disease risk assessment 6 weeks after risk disclosure, 75 (47.5%) believed their Alzheimer disease risk was more than 5% points different from the Alzheimer disease risk estimate they were given. 2 key findings →
Design: randomized controlled trial Participants: 158 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Patients treated with LY451395 did not show a statistically significant separation from patients taking placebo on the Alzheimer's Disease Assessment Scale-Cognitive Subscale, the primary outcome measure. 3 key findings →
Participants: 90 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This cost-consequence analysis reveals economic benefits of treatment of moderate to severe AD with donepezil. 1 key finding →
Participants: 144 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Medial temporal lobe atrophy seems to be a more important predictor of cognition than small-vessel disease in MCI. 4 key findings →
Design: cohort study Participants: 896 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer disease (AD) has a significant impact on caregivers. 5 key findings →
Participants: 1,059 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
We found some evidence that n-3 PUFAs might be beneficial for the maintenance of executive functioning in older adults at risk of dementia with low omega-3 index, but this exploratory finding requires further confirmation. 3 key findings →
Design: randomized controlled trial Participants: 183 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Our analysis extends recent work by revealing specific benefits for instrumental activities of daily living for individuals in the early stages of AD and supports the value of exercise for individuals with cognitive impairment. 4 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
For the intention-to-treat analysis, 60 patients between ages 51 and 82 years (mean [SD], 70.65 [8.16] years; 30 females; 30 males) were included. 5 key findings →
Participants: 30 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Maintaining optimal cognitive functioning throughout the lifespan is a public health priority. 3 key findings →
Design: randomized controlled trial Participants: 72 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
This double-blind randomized controlled trial of vitamin therapy demonstrates a strong correlation between serum tHcy and plasma Abeta40 concentrations in subjects with ischemic stroke. 4 key findings →
Design: randomized controlled trial Participants: 150 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
This cluster randomized clinical trial found that despite high adherence to the training, a multicomponent intervention promoting goal-directed care for suspected UTIs and LRIs did not significantly reduce antimicrobial use among nursing home residents with advanced dementia. 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Median (IQR) eGFR was 73(60-84) mL/min/1.73 m 2 . 3 key findings →
Design: longitudinal study Participants: 1,334 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Addressing the need for rigorous longitudinal data for the effectiveness of music therapy in people with and at risk for developing AD, this trial aims to enhance knowledge regarding cost-effective interventions with potentially high clinical applicability. 5 key findings →
Design: randomized controlled trial Participants: 84 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Etalanetug presented an adequate safety and immunogenicity profile in healthy adults. 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Physical exercise and cognitive and social enrichment activities can enhance cognitive function in patients with chronic stroke, but their cost-effectiveness compared with a balance and tone program is uncertain. 5 key findings →
Participants: 120 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Change in occupational performance predicted change in depressive symptoms. 5 key findings →
Design: randomized controlled trial Participants: 20 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The Continuum: Dementia for Medical Students curriculum provided an inexpensive and readily implementable means for improving medical knowledge of dementia. 2 key findings →
Design: longitudinal study Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →